Quoin Pharmaceuticals Ltd.
QNRX | NASDAQ
$6.90
-$0.16 (-2.27%)
At close: Sep 21, 2026, 4:00 PM ET
$7.23
+$0.33 (+4.78%)
After-hours:
Sep 21, 2026, 7:34 PM ET
Company Profile
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Key Executives
| Name | Position |
|---|---|
| Michael Myers | Co-Founder, Chief Executive Officer & Chairman |
| Denise Carter | Co-Founder, Chief Operating Officer & Director |
| Sally Lawlor | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 20, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 8-K | Current Report |
| Jul 16, 2026 | ARS | Filing |
Quoin Pharmaceuticals Ltd.
| Country | United States |
| IPO Date | Jul 31, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Michael Myers |
Contact Details
42127 Pleasant Forest Court Ashburn,
Virginia 20148-7349 United States
Stock Details
| Ticker Symbol | QNRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671502 |
| CUSIP Number | 74907L409 |
| ISIN Number | US74907L4095 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove QNRX